Bioidentical hormone therapy: An assessment of provider knowledge

Julia A. Files, Lisa N. Kransdorf, Marcia Ko, Juliana M. Kling, Paru S. David, Sandhya Pruthi, Richa Sood, Douglas Creedon, Yu Hui H Chang, Anita P. Mayer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives Bioidentical hormone therapy (BHT) is available in the United States in formulations that have been approved by the Food and Drug Administration (FDA) but also in formulations that have not been so approved. The aim of this study was to evaluate the knowledge, beliefs, and prescribing practices of BHT among healthcare providers. Study design A cross-sectional self-selected responder survey was conducted of health care providers attending primary care Continuing Medical Education (CME) conferences in the United States from May 2012 to April 2013. The questionnaire consisted of 26 items assessing knowledge, beliefs, and current practice around BHT. Results A total of 366 survey responses were analyzed. Though 69.8% of respondents accurately identified the definition of BHT, only 45.3% were aware that BHT is available in FDA-approved products and 34.2% of respondents incorrectly identified that BHT is available only in custom-compounded formulations. Of those who had prescribed CC-BHT, less than half agreed with the statement “I am comfortable prescribing BHT” (45.4%). Conclusions Our study showed that many practitioners are unaware that bioidentical hormones are available in FDA-approved products. Knowledge gaps identified by this survey highlight the need for and importance of education to further dispel misinformation surrounding the topic.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalMaturitas
Volume94
DOIs
StatePublished - Dec 1 2016

Fingerprint

Hormones
United States Food and Drug Administration
Therapeutics
Health Personnel
Medical education
Continuing Medical Education
Health care
Surveys and Questionnaires
Primary Health Care
Education
Communication

Keywords

  • Bioidentical
  • Compounded
  • Hormone therapy
  • Menopause

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Obstetrics and Gynecology

Cite this

Files, J. A., Kransdorf, L. N., Ko, M., Kling, J. M., David, P. S., Pruthi, S., ... Mayer, A. P. (2016). Bioidentical hormone therapy: An assessment of provider knowledge. Maturitas, 94, 46-51. https://doi.org/10.1016/j.maturitas.2016.08.014

Bioidentical hormone therapy : An assessment of provider knowledge. / Files, Julia A.; Kransdorf, Lisa N.; Ko, Marcia; Kling, Juliana M.; David, Paru S.; Pruthi, Sandhya; Sood, Richa; Creedon, Douglas; Chang, Yu Hui H; Mayer, Anita P.

In: Maturitas, Vol. 94, 01.12.2016, p. 46-51.

Research output: Contribution to journalArticle

Files, JA, Kransdorf, LN, Ko, M, Kling, JM, David, PS, Pruthi, S, Sood, R, Creedon, D, Chang, YHH & Mayer, AP 2016, 'Bioidentical hormone therapy: An assessment of provider knowledge', Maturitas, vol. 94, pp. 46-51. https://doi.org/10.1016/j.maturitas.2016.08.014
Files, Julia A. ; Kransdorf, Lisa N. ; Ko, Marcia ; Kling, Juliana M. ; David, Paru S. ; Pruthi, Sandhya ; Sood, Richa ; Creedon, Douglas ; Chang, Yu Hui H ; Mayer, Anita P. / Bioidentical hormone therapy : An assessment of provider knowledge. In: Maturitas. 2016 ; Vol. 94. pp. 46-51.
@article{e0570ca470934ab4b7cf07f773c9b639,
title = "Bioidentical hormone therapy: An assessment of provider knowledge",
abstract = "Objectives Bioidentical hormone therapy (BHT) is available in the United States in formulations that have been approved by the Food and Drug Administration (FDA) but also in formulations that have not been so approved. The aim of this study was to evaluate the knowledge, beliefs, and prescribing practices of BHT among healthcare providers. Study design A cross-sectional self-selected responder survey was conducted of health care providers attending primary care Continuing Medical Education (CME) conferences in the United States from May 2012 to April 2013. The questionnaire consisted of 26 items assessing knowledge, beliefs, and current practice around BHT. Results A total of 366 survey responses were analyzed. Though 69.8{\%} of respondents accurately identified the definition of BHT, only 45.3{\%} were aware that BHT is available in FDA-approved products and 34.2{\%} of respondents incorrectly identified that BHT is available only in custom-compounded formulations. Of those who had prescribed CC-BHT, less than half agreed with the statement “I am comfortable prescribing BHT” (45.4{\%}). Conclusions Our study showed that many practitioners are unaware that bioidentical hormones are available in FDA-approved products. Knowledge gaps identified by this survey highlight the need for and importance of education to further dispel misinformation surrounding the topic.",
keywords = "Bioidentical, Compounded, Hormone therapy, Menopause",
author = "Files, {Julia A.} and Kransdorf, {Lisa N.} and Marcia Ko and Kling, {Juliana M.} and David, {Paru S.} and Sandhya Pruthi and Richa Sood and Douglas Creedon and Chang, {Yu Hui H} and Mayer, {Anita P.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.maturitas.2016.08.014",
language = "English (US)",
volume = "94",
pages = "46--51",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Bioidentical hormone therapy

T2 - An assessment of provider knowledge

AU - Files, Julia A.

AU - Kransdorf, Lisa N.

AU - Ko, Marcia

AU - Kling, Juliana M.

AU - David, Paru S.

AU - Pruthi, Sandhya

AU - Sood, Richa

AU - Creedon, Douglas

AU - Chang, Yu Hui H

AU - Mayer, Anita P.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objectives Bioidentical hormone therapy (BHT) is available in the United States in formulations that have been approved by the Food and Drug Administration (FDA) but also in formulations that have not been so approved. The aim of this study was to evaluate the knowledge, beliefs, and prescribing practices of BHT among healthcare providers. Study design A cross-sectional self-selected responder survey was conducted of health care providers attending primary care Continuing Medical Education (CME) conferences in the United States from May 2012 to April 2013. The questionnaire consisted of 26 items assessing knowledge, beliefs, and current practice around BHT. Results A total of 366 survey responses were analyzed. Though 69.8% of respondents accurately identified the definition of BHT, only 45.3% were aware that BHT is available in FDA-approved products and 34.2% of respondents incorrectly identified that BHT is available only in custom-compounded formulations. Of those who had prescribed CC-BHT, less than half agreed with the statement “I am comfortable prescribing BHT” (45.4%). Conclusions Our study showed that many practitioners are unaware that bioidentical hormones are available in FDA-approved products. Knowledge gaps identified by this survey highlight the need for and importance of education to further dispel misinformation surrounding the topic.

AB - Objectives Bioidentical hormone therapy (BHT) is available in the United States in formulations that have been approved by the Food and Drug Administration (FDA) but also in formulations that have not been so approved. The aim of this study was to evaluate the knowledge, beliefs, and prescribing practices of BHT among healthcare providers. Study design A cross-sectional self-selected responder survey was conducted of health care providers attending primary care Continuing Medical Education (CME) conferences in the United States from May 2012 to April 2013. The questionnaire consisted of 26 items assessing knowledge, beliefs, and current practice around BHT. Results A total of 366 survey responses were analyzed. Though 69.8% of respondents accurately identified the definition of BHT, only 45.3% were aware that BHT is available in FDA-approved products and 34.2% of respondents incorrectly identified that BHT is available only in custom-compounded formulations. Of those who had prescribed CC-BHT, less than half agreed with the statement “I am comfortable prescribing BHT” (45.4%). Conclusions Our study showed that many practitioners are unaware that bioidentical hormones are available in FDA-approved products. Knowledge gaps identified by this survey highlight the need for and importance of education to further dispel misinformation surrounding the topic.

KW - Bioidentical

KW - Compounded

KW - Hormone therapy

KW - Menopause

UR - http://www.scopus.com/inward/record.url?scp=84985910999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985910999&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2016.08.014

DO - 10.1016/j.maturitas.2016.08.014

M3 - Article

C2 - 27823744

AN - SCOPUS:84985910999

VL - 94

SP - 46

EP - 51

JO - Maturitas

JF - Maturitas

SN - 0378-5122

ER -